Anandamide, formally designated as N-arachidonoylethanolamine (AEA), represents one of the most transformative discoveries in modern neurobiology and neuropsychiatry. As the premier endogenous ligand identified for central cannabinoid receptors, this lipid-derived neurotransmitter orchestrates fundamental physiological processes ranging from emotional homeostasis and fear extinction to nociception and neuroplasticity. Understanding the synthesis, signaling cascades, and enzymatic degradation of AEA offers critical insights into the biological underpinnings of affective disorders, stress resilience, and human cognition.
Anandamide (N-Arachidonoylethanolamine / AEA)
1. Concise Definition
Anandamide (AEA) is an endogenous lipid neurotransmitter belonging to the class of endocannabinoids, structurally classified as an ethanolamide of arachidonic acid. It serves as a partial agonist at type 1 and type 2 cannabinoid receptors (CB1 and CB2), functioning primarily as a retrograde messenger across central and peripheral synaptic junctions.
Unlike classical neurotransmitters that are pre-synthesized and sequestered within presynaptic storage vesicles, AEA is generated on demand from membrane phospholipid precursors in response to intracellular calcium influx or G-protein-coupled receptor activation. Once synthesized in postsynaptic dendritic regions, it diffuses retrogradely across the synaptic cleft to bind presynaptic CB1 receptors, transiently or persistently dampening the release of primary neurotransmitters such as gamma-aminobutyric acid (GABA) and glutamate.
Beyond its interactions with canonical cannabinoid receptors, AEA serves as an agonist at transient receptor potential vanilloid 1 (TRPV1) channels and modulates peroxisome proliferator-activated receptors (PPARs). Through these pleiotropic actions, AEA acts as a master regulator of synaptic transmission, playing an indispensable role in emotional homeostasis, pain perception, neuroprotection, and reward signaling throughout the mammalian central nervous system.
2. Etymology & Linguistic Origin
The term anandamide is a portmanteau coined by the research team that isolated the compound in 1992. The prefix derives from the Sanskrit noun ānanda (आनन्द), signifying “bliss,” “supreme joy,” or “divine delight.” This philosophical and spiritual root reflects the profound euphoria, calm, and affective equilibrium associated with cannabinoid receptor stimulation in neurobiological models.
The chemical suffix -amide stems from classical chemical nomenclature, indicating that the molecule is an organic compound containing an acyl group linked to a nitrogen atom. Chemically, it describes the condensation product of arachidonic acid (a polyunsaturated omega-6 fatty acid) and ethanolamine, yielding the formal systematic nomenclature N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide, commonly abbreviated as AEA.
The introduction of this name into the scientific lexicon established an evocative bridge between ancient Eastern conceptualizations of serene mental states and modern biochemical pharmacology. It highlighted from its inception the unique association between this endogenous compound and emotional tranquility, hedonic tone, and mental restoration.
3. Pronunciation & Grammatical Form
Pronunciation: Phonetically transcribed as /əˈnændəmaɪd/ (uh-NAN-duh-myde) in International Phonetic Alphabet (IPA) format. The acronym AEA is pronounced by articulating each individual letter: /ˌeɪ.iːˈeɪ/.
Grammatical Form: Anandamide is an uncountable, singular mass noun. In biomedical prose, it functions primarily as a noun or an attributive noun (e.g., “anandamide signaling,” “anandamide tone,” “anandamide-induced analgesia”). Derived adjectives include anandamidergic (pertaining to or mediated by anandamide transmission), though researchers more frequently deploy broader classifications such as endocannabinergic.
4. Detailed Conceptual Explanation
The conceptual framework of anandamide is inextricably bound to the discovery of backward, or retrograde, neurotransmission. Throughout most of the twentieth century, the central dogma of neurobiology dictated that synaptic communication operated in a strictly unidirectional manner: action potentials depolarized presynaptic boutons, provoking the exocytosis of vesicles containing classical transmitters into the cleft to engage postsynaptic receptors. The elucidation of AEA dismantled this unidirectional model by demonstrating that the postsynaptic dendrite can directly influence presynaptic release probabilities through lipid-derived signaling agents.
When a postsynaptic neuron undergoes sustained depolarization or intense activation of Gq/11-coupled receptors—such as group I metabotropic glutamate receptors (mGluRs) or M1/M3 muscarinic acetylcholine receptors—intracellular calcium ([Ca2+]i) levels rise precipitously. This biochemical trigger mobilizes specific phospholipases, most notably N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD). NAPE-PLD cleaves the membrane precursor N-arachidonoyl phosphatidylethanolamine to liberate free AEA directly into the lipid bilayer and intracellular space.
Because AEA is highly lipophilic, it readily traverses the plasma membrane and enters the extracellular synaptic cleft. It travels backward across the synaptic divide to bind the extracellular loops of CB1 receptors anchored on the presynaptic terminal. CB1 receptors are inhibitory G-protein-coupled receptors (Gi/o). Activation of the presynaptic CB1 receptor leads to the dissociation of the Gβγ subunit, which directly inhibits presynaptic voltage-gated calcium channels (VGCCs) and activates inwardly rectifying potassium channels. This hyperpolarizes the presynaptic terminal, dramatically decreasing the probability of further neurotransmitter exocytosis.
This retrograde feedback loop operates over two primary temporal scales: short-term plasticity and long-term depression. In short-term plasticity, anandamide transiently inhibits transmitter release for hundreds of milliseconds to several seconds, known as Depolarization-Induced Suppression of Inhibition (DSI) at GABAergic synapses, or Depolarization-Induced Suppression of Excitation (DSE) at glutamatergic synapses. In long-term forms of synaptic plasticity, prolonged activation of presynaptic CB1 receptors by AEA initiates downstream protein kinase cascades that permanently downregulate neurotransmitter release machinery, contributing to forms of long-term depression (LTD) essential for memory pruning and emotional learning.
The biological action of AEA is tightly constrained both spatially and temporally. Unlike classical transmitters that remain active until cleared by high-affinity reuptake transporters, AEA relies on passive or carrier-mediated cellular uptake followed by immediate intracellular catabolism. The primary clearing enzyme is fatty acid amide hydrolase (FAAH), an integral membrane enzyme localized predominantly on the endoplasmic reticulum of postsynaptic structures. FAAH rapidly hydrolyzes AEA into arachidonic acid and ethanolamine, effectively extinguishing the signaling event and maintaining basal endocannabinoid tone within precise physiological boundaries.
5. Historical Development
The historical trajectory of anandamide begins with the quest to understand how delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis sativa, exerts its effects on the brain. For decades, researchers debated whether THC functioned non-specifically by disrupting the fluidity of neuronal lipid membranes or by engaging a selective, stereospecific protein receptor.
A critical breakthrough occurred in 1988, when Allyn Howlett and William Devane utilized radioligand binding assays to conclusively demonstrate the presence of specific, high-affinity cannabinoid binding sites in rat cerebral cortex membranes. In 1990, Lisa Matsuda and colleagues successfully cloned the complementary DNA encoding this central receptor, officially designated as the CB1 receptor. The identification of a dedicated G-protein-coupled receptor logically implied the existence of an endogenous ligand; the mammalian brain could not have evolved a specialized neuroreceptor solely to respond to a plant-derived cannabinoid.
In 1992, at the Hebrew University of Jerusalem, a research team led by the renowned pharmacologist Raphael Mechoulam, working alongside postdoctoral fellows William Devane and Lumír Hanuš, succeeded in isolating the endogenous molecule. Purifying small amounts of active material from thousands of porcine brains, they determined the chemical structure of the purified active fraction via mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. They confirmed that this lipid derivative bound selectively to the CB1 receptor and produced pharmacological effects mimicking THC, publishing their seminal discovery in Science.
Subsequent decades saw rapid expansions in the characterization of anandamide’s life cycle. In 1996, Benjamin Cravatt and his research group cloned and characterized FAAH, elucidating the primary mechanism governing AEA termination. In the early 2000s, retrograde endocannabinoid signaling was conclusively mapped through electrophysiological studies by Alger, Nicoll, and Kano, solidifying AEA’s role as a core component of activity-dependent synaptic plasticity. Today, research focuses heavily on targeting the AEA signaling network for therapeutic interventions in anxiety, post-traumatic stress, and chronic neuroinflammatory conditions.
6. Theoretical Foundations
The neurobiological conceptualization of anandamide is embedded within three primary theoretical frameworks: the Retrograde Messenger Paradigm, the Allostatic Stress Buffer Theory, and the Clinical Endocannabinoid Deficiency (CECD) Hypothesis.
The Retrograde Messenger Paradigm redefined traditional concepts of synaptic organization. In this model, neural networks utilize target-derived feedback to stabilize circuit gain and prevent excitotoxicity. When excitatory drive becomes excessive, localized postsynaptic production of AEA dampens upstream inputs without requiring widespread, metabolically expensive, network-wide inhibition. This mechanism establishes a homeostatic buffer that prevents runaway excitation while enabling selective, activity-dependent structural remodeling.
The Allostatic Stress Buffer Theory conceptualizes the anandamidergic system as a gatekeeper of the hypothalamic-pituitary-adrenal (HPA) axis. Under resting, baseline conditions, tonic AEA signaling within the basolateral amygdala, prefrontal cortex, and hippocampus exerts an ongoing inhibitory restraint on corticotropin-releasing hormone (CRH) neurons. When an organism encounters an acute stressor, localized FAAH activity surges, rapidly degrading AEA and relieving this tonic inhibition. This permits the rapid mounting of an adaptive fight-or-flight endocrine response. As the stressor resolves, AEA synthesis resumes, restoring basal tone, facilitating the extinction of acute fear associations, and re-establishing emotional homeostasis.
The Clinical Endocannabinoid Deficiency (CECD) framework, formulated by Ethan Russo, posits that an underlying systemic deficit in endocannabinoid tone—characterized by subnormal AEA concentrations, receptor downregulation, or accelerated FAAH catabolism—may constitute the common pathophysiology underlying several treatment-resistant functional syndromes. Disorders such as fibromyalgia, irritable bowel syndrome (IBS), and migraine headaches are hypothesized to stem from a baseline failure of AEA to appropriately regulate sensory thresholds, gastrointestinal motility, and neurovascular inflammation.
7. Key Components, Types & Dimensions
The biological life cycle and operational domains of anandamide encompass several distinct molecular components, biochemical pathways, and functional receptor targets:
- Biosynthetic Pathways: Primarily governed by the calcium-dependent enzyme N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD), alongside auxiliary parallel pathways involving phospholipase C (PLC) and alpha/beta-hydrolase domain containing 4 (ABHD4).
- Receptor Targets:
- Cannabinoid Receptor Type 1 (CB1): High density in the basal ganglia, substantia nigra, cerebellum, hippocampus, and cerebral cortex; mediates psychotropic modulation, motor control, memory consolidation, and appetite.
- Cannabinoid Receptor Type 2 (CB2): Predominantly expressed in peripheral lymphoid organs and central microglial cells; acts as a pivotal regulator of neuroimmune activation and cytokine suppression.
- Transient Receptor Potential Vanilloid 1 (TRPV1): An ionotropic channel involved in thermosensation and pain; intracellular AEA acts as an “endovanilloid” agonist, modulating nociceptive signaling.
- Peroxisome Proliferator-Activated Receptors (PPAR-alpha and PPAR-gamma): Nuclear hormone receptors engaged by AEA to regulate lipid metabolism, anti-inflammatory gene transcription, and long-term neuroprotection.
- Clearance and Catabolism: Rapidly internalized by an putative Endocannabinoid Membrane Transporter (EMT) and primarily cleaved into arachidonic acid and ethanolamine by Fatty Acid Amide Hydrolase (FAAH). A secondary pathway involves oxidation via cyclooxygenase-2 (COX-2) into pro-inflammatory prostaglandin ethanolamides (prostamides).
- Functional Dimensions: Encompasses tonic versus phasic signaling. Tonic AEA signaling maintains baseline mood, vascular tone, and basal pain thresholds, while phasic bursts modulate specific synaptic events, such as acute behavioral responses to fear or reward cues.
8. Examples & Illustrative Cases
The physiological influence of anandamide is illustrated across both normative human behavioral experiences and psychiatric conditions:
Case 1: The Neurobiology of the “Runner’s High”
For decades, exercise-induced euphoria and analgesia were attributed exclusively to peripheral endorphin release. However, beta-endorphins cannot cross the blood-brain barrier in significant quantities. Contemporary exercise physiology studies demonstrate that prolonged aerobic exertion triggers substantial increases in circulating plasma AEA levels. Because AEA is a small, lipophilic molecule, it freely permeates the blood-brain barrier, activating central CB1 receptors in the limbic system to induce mild euphoria, anxiolysis, and elevated pain thresholds during endurance sports.
Case 2: The FAAH C385A Single Nucleotide Polymorphism
A well-documented genetic variant in the human population involves a missense mutation (rs324420) in the FAAH gene, converting a cytosine to an adenine (C385A). Individuals who are homozygous or heterozygous for the A allele express a destabilized FAAH enzyme that is degraded more rapidly by cellular proteasomes. Consequently, these individuals possess constitutively elevated resting levels of anandamide. Clinically, carriers exhibit reduced baseline anxiety, enhanced functional connectivity between the ventromedial prefrontal cortex and amygdala, accelerated fear extinction in laboratory conditioning tasks, and lower vulnerability to substance abuse disorders.
Case 3: Fear Conditioning and PTSD Pathology
Consider a clinical case of post-traumatic stress disorder (PTSD). During trauma exposure, associative learning links neutral environmental cues with extreme threat. Healthy recovery requires fear extinction—the gradual learning that the cue no longer predicts danger. In clinical cohorts with PTSD, peripheral and central AEA levels are frequently blunted. When exposed to trauma reminders in extinction therapy, the deficiency in localized AEA synthesis in the basolateral amygdala prevents the downregulation of presynaptic glutamate release, leaving hyperactive fear circuits active and severely impairing extinction recall.
9. Measurement & Assessment
Quantifying anandamide presents significant technical challenges due to its low physiological concentrations (typically in the low nanomolar to picomolar range), rapid enzymatic degradation, and marked hydrophobicity. Biological assessment methodologies have advanced considerably across biochemical and neuroimaging domains:
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): The undisputed gold standard for quantifying AEA in biological matrices, including blood plasma, serum, cerebrospinal fluid (CSF), and homogenized brain tissue. Samples require rapid stabilization, low-temperature handling, and solid-phase extraction (SPE) to prevent ex vivo synthesis or enzymatic degradation prior to chromatographic separation and selective reaction monitoring.
Enzyme-Linked Immunosorbent Assays (ELISA): Commercial competitive ELISA kits offer semi-quantitative screening of AEA levels in plasma and cell culture supernatants. While accessible for high-throughput screening, cross-reactivity with structurally related fatty acid ethanolamides (such as oleoylethanolamide and palmitoylethanolamide) requires careful validation against mass spectrometric baselines.
Positron Emission Tomography (PET) Imaging: While direct radiolabeling of native AEA for in vivo tracking is limited by rapid metabolism, indirect assessment of the anandamidergic system is achieved using selective PET radioligands for the CB1 receptor (e.g., [11C]OMAR, [18F]FMPEP-d2) and FAAH enzyme activity (e.g., [11C]CURB). Reductions in [11C]CURB binding indicate lower FAAH expression, inferring elevated local anandamide availability within specific neuroanatomical regions.
10. Applications & Practical Significance
Modulation of the anandamide signaling pathway represents an active frontier across multiple domains of clinical and translational medicine:
Neuropsychiatry and Affective Disorders: Rather than directly administering non-selective, exogenous CB1 agonists—which risk triggering tolerance, motor impairment, and psychotomimetic effects—pharmacologists prioritize targeted FAAH inhibitors (e.g., URB597, PF-04457845). By inhibiting the breakdown of AEA, these compounds selectively amplify endogenous anandamide signaling strictly at sites where it is being actively synthesized, producing therapeutic anxiolytic, antidepressant, and fear-extinguishing effects without the intoxication linked to synthetic cannabinoids.
Pain Management and Nociception: Anandamide directly suppresses nociceptive transmission at dorsal horn spinal synapses and mitigates neurogenic inflammation via peripheral CB1 and CB2 activation. Dual inhibitors that target both FAAH and cyclooxygenase (COX) enzymes, or inhibitors of both FAAH and soluble epoxide hydrolase, are under investigation as non-opioid therapeutics for neuropathic pain, inflammatory arthritis, and diabetic neuropathy.
Addiction and Substance Use Disorders: Augmenting AEA tone helps normalize dysregulated mesolimbic dopamine firing during substance withdrawal. Elevated AEA assists in attenuating stress-induced craving and relapse vulnerability across dependencies on alcohol, nicotine, and opioids.
11. Research & Empirical Evidence
Substantial empirical investigations corroborate the foundational role of anandamide across cognitive and behavioral neuroscience:
In a landmark human translational trial, Dincheva et al. (2015) examined the behavioral and neural consequences of the human FAAH C385A variant. Utilizing functional magnetic resonance imaging (fMRI), the researchers demonstrated that individuals carrying the low-expression FAAH allele exhibited significantly enhanced fronto-amygdala connectivity and displayed rapid, robust fear extinction. Complementary knock-in mouse models carrying the exact human polymorphism recapitulated these precise affective phenotypes, providing causal proof that elevated endogenous AEA enhances emotional resilience.
Research by Mayo et al. (2020) evaluated the therapeutic efficacy of selective FAAH inhibition in clinical cohorts diagnosed with PTSD. Patients receiving the FAAH inhibitor PF-04457845 demonstrated enhanced consolidation of fear extinction memories and marked resistance to stress-induced recall reactivation compared to placebo controls. This confirmed that preserving endogenous anandamide tone directly promotes adaptive emotional memory updating in humans.
In the domain of metabolic and stress physiology, Hill et al. (2010) established that chronic, unpredictable stress in rodent models causes widespread down-regulation of AEA signaling within the hippocampus, hypothalamus, and prefrontal cortex. This reduction directly correlated with the development of anhedonia, passive coping strategies, and hyperactive HPA-axis output, demonstrating that persistent exhaustion of anandamide tone is a central pathophysiological feature of stress-induced depression.
12. Cultural & Cross-Cultural Considerations
The cultural framework surrounding anandamide exists at the intersection of traditional botanical medicine, indigenous knowledge systems, and modern neuroscientific discourse. The initial characterization of the endocannabinoid system provided an evolutionary and biological rationale for humanity’s multi-millennial relationship with the cannabis plant, which has been documented across ancient Indian, Chinese, and Middle Eastern pharmacopeias.
In classical Ayurvedic traditions, cannabis preparations (such as Bhang) were classified as agents capable of dispelling sorrow, harmonizing internal humors, and producing deep spiritual tranquility. The naming of the compound as anandamide by Mechoulam and his team intentionally acknowledged these ancient insights, providing a cross-temporal validation of indigenous observations regarding cannabinoid-mediated affective states.
Furthermore, human population genetics reveals notable cross-cultural and geographical variations in the distribution of the FAAH C385A single nucleotide polymorphism. Populations of European and Asian descent display varying allele frequencies, which some evolutionary anthropologists hypothesize may interact with cultural stressors, societal collectivism, and regional rates of affective disorders. However, scholars must avoid biological determinism; the phenotypic translation of endocannabinoid genetics is consistently shaped by environmental adversity, socioeconomic variables, and culture-specific coping strategies.
13. Criticisms, Debates & Limitations
Despite three decades of intensive research, several critical debates and pharmacological controversies persist regarding the therapeutic viability and functional profile of AEA:
The Failure of Clinical FAAH Trials: The most significant controversy surrounding the clinical translation of AEA biology occurred in 2016 during a French Phase 1 clinical trial of BIA 10-2474, a putative fatty acid amide hydrolase inhibitor. The compound caused severe neurotoxicity, resulting in the death of one participant and permanent neurological injury in four others. Subsequent mechanistic investigations revealed that the compound’s off-target inhibition of multiple other brain serine hydrolases—rather than the elevation of AEA itself—caused the disaster. Nevertheless, this tragedy highlighted the immense challenges of achieving absolute target selectivity when manipulating lipid catabolism.
The AEA vs. 2-AG Functional Dichotomy: While AEA was the first endocannabinoid discovered, 2-Arachidonoylglycerol (2-AG) is present in the mammalian central nervous system at concentrations roughly two to three orders of magnitude higher than AEA. 2-AG acts as a high-efficacy full agonist at both CB1 and CB2 receptors, leading some neuroscientists to argue that 2-AG is the primary retrograde messenger mediating classical DSI and DSE, while AEA primarily acts as an auxiliary, fine-tuning modulator or tonic homeostatic regulator. Determining the exact division of labor between these two lipids remains an area of ongoing debate.
The Vanilloid Paradox: Unlike classical cannabinoids, AEA binds and activates intracellular TRPV1 receptors, which typically mediate neurogenic inflammation and nociceptive signaling. Consequently, under certain pathological or concentration-dependent conditions, elevated AEA can provoke pro-inflammatory and pro-nociceptive actions through TRPV1, counteracting its CB1-mediated analgesic and anti-inflammatory properties.
14. Related Terms & Distinctions
Understanding anandamide requires contextualizing it alongside related endocannabinoids, receptors, and phytocannabinoids:
- 2-Arachidonoylglycerol (2-AG): The second major endogenous cannabinoid. Unlike AEA, which is a partial CB1 agonist synthesized via NAPE-PLD and degraded by FAAH, 2-AG is a full agonist synthesized via diacylglycerol lipase (DAGL) and primarily metabolized by monoacylglycerol lipase (MAGL).
- Delta-9-Tetrahydrocannabinol (THC): The primary exogenous phytocannabinoid in cannabis. While both AEA and THC bind to the orthosteric site of the CB1 receptor, THC has a significantly longer metabolic half-life, does not undergo spatial-temporal clearance by FAAH, and causes profound psychotropic intoxication, memory disruption, and receptor downregulation not observed with physiological AEA signaling.
- Oleoylethanolamide (OEA) & Palmitoylethanolamide (PEA): Structural fatty acid ethanolamide cousins of AEA. Neither compound exhibits significant binding affinity for CB1 or CB2 receptors; instead, they signal primarily through PPAR-alpha and GPR119 to modulate peripheral satiety, lipid metabolism, and local tissue inflammation.
- Cannabidiol (CBD): A non-intoxicating phytocannabinoid. CBD does not bind directly to the orthosteric site of CB1 with high affinity; instead, it functions as a negative allosteric modulator of CB1 and acts as a weak inhibitor of FAAH-mediated cellular uptake and breakdown, which may indirectly elevate endogenous AEA levels.
15. Summary / Key Takeaways
Anandamide (AEA) represents an indispensable pillar of modern molecular neuroscience, providing the biological mechanism that connects retrograde synaptic transmission to psychological resilience, pain modulation, and emotional regulation. Synthesized on demand from membrane phospholipids and rapidly cleared by FAAH, AEA operates as a localized homeostatic stabilizer that prevents neuronal excitotoxicity and buffers against the neuroendocrine consequences of stress.
The therapeutic potential of modulating anandamide tone—principally through selective enzyme inhibition rather than direct, non-specific receptor stimulation—remains one of the most promising avenues for the treatment of refractory anxiety, PTSD, chronic pain, and neuroinflammatory disorders. As analytical technologies and targeted pharmacology continue to mature, deciphering the precise temporal and spatial dynamics of this “bliss molecule” will deepen our understanding of emotional balance and human mental health.
References
- Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949. https://doi.org/10.1126/science.1470919
- Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Lichtman, A. H. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384(6604), 83–87. https://doi.org/10.1038/384083a0
- Dincheva, I., Drysdale, A. T., Hartley, C. A., Johnson, D. C., Jing, D., King, E. C., Ra, S., Gray, J. M., Yang, R., DeGruccio, A. M., Huang, C., Patil, S. S., Glatt, C. E., Lee, F. S., & Casey, B. J. (2015). FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nature Communications, 6, Article 6395. https://doi.org/10.1038/ncomms7395
- Hill, M. N., Patel, S., Campolongo, P., Tasker, J. G., Wotjak, C. T., & Bains, J. S. (2010). Functional interactions between stress and the endocannabinoid system: From synaptic signaling to behavioral output. The Journal of Neuroscience, 30(45), 14980–14986. https://doi.org/10.1523/JNEUROSCI.4283-10.2010
- Mayo, L. M., Asratian, A., Lindé, J., Morena, M., Haataja, R., Hammar, A. S., Augier, G., Petrie, G. N., Stensson, N., Hill, M. N., & Heilig, M. (2020). Elevated anandamide, enhanced recall of fear extinction, and attenuated stress reactivity following inhibition of fatty acid amide hydrolase: A randomized, controlled experimental medicine trial. Biological Psychiatry, 87(6), 538–547. https://doi.org/10.1016/j.biopsych.2019.07.034
- Russo, E. B. (2016). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant conditions. Cannabis and Cannabinoid Research, 1(1), 154–165. https://doi.org/10.1089/can.2016.0009